Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Boi, Michela; Todaro, Maria; Vurchio, Valentina; Yang, Shao Ning; Moon, John; Kwee, Ivo; Rinaldi, Andrea; Pan, Heng; Crescenzo, Ramona; Cheng, Mangeng; Cerchietti, Leandro; Elemento, Olivier; Riveiro, Maria E; Cvitkovic, Esteban; Bertoni, Francesco; Inghirami, Giorgio.
; 7(48): 79637-79653, 2016 Nov 29.
Artigo em Inglês | MEDLINE | ID: mdl-27793034
Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.
ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2.
Long-term survival of a child with refractory anaplastic large cell lymphoma following therapy with an antisense oligonucleotide, topotecan, and vinblastine.
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma.
Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma.
Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.